A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Patients With Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS)
Latest Information Update: 29 May 2025
At a glance
- Drugs Efgartigimod alfa (Primary)
- Indications Postural orthostatic tachycardia syndrome
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms ALPHA
- Sponsors argenx
Most Recent Events
- 23 May 2025 AR added as trial focus after results gets published.
- 02 Sep 2024 Trial design presented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology
- 17 Jun 2024 According to an argenx media release, based on Phase 2 ALPHA data, argenx will not move forward with development in PC-POTS and plans to prioritize resources to the nearly 50 active clinical trials in its expanding pipeline.